U.S. markets are recovering from last week’s slide, helped by hopes of a U.S.-China trade resolution. As the government shutdown limits general economic news, investors’ attention turns to the upcoming third quarter results. Which undervalued stocks could present buying opportunities?
Are you looking for concrete business ideas to deal with the current market volatility? Subscribe here to unlock access to InvestingPro’s AI-selected stock winners.
US stock markets are rebounding from last week’s sharp decline following the announcement of Chinese restrictions on exports of rare earth metals. Investors appear to be hoping that this is part of ongoing negotiations with the United States, which would reduce the risk of a deeper decline in the near term. As the US government shutdown silences general economic news, attention is now focused on quarterly results, especially as major financial companies release their results.
Today’s analysis focuses on three potentially undervalued companies expected to report third-quarter 2025 results in the coming weeks.
Comcast Corp nears long-term lows
made the list not only for its high fair value of 58%, but also for its technical setup. The stock has been in a downtrend for nearly a year and is nearing its 2022 low, around $29 per share.
If the stock maintains this level and reports strong quarterly results, this could be a good opportunity to consider a buy. The low P/E ratio of 4.8x and recent net profit well above the average of previous years make it even more attractive.
The strong fundamentals of Regeneron Pharmaceuticals
is a biotechnology and medical device company focused on innovative treatments. The company is working with partners on gene therapy research, which is a key focus for the future. Its fair value potential is 35.5% and its financial health is solid.
Source: InvestPro
In June, the stock hit the low point of a less-than-year-old downtrend, around $480 per share, which could lead to a rebound. A break above $600 per share would be key to a potential upward trend.
Analysts’ confidence in Arch Capital
is highlighted today for its fair value of 27% and its solid financial health, like Regeneron….
..
